DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Oxsoralen Topical (Methoxsalen Topical) - Summary



Each ml. of Oxsoralen Lotion contains 10 mg methoxsalen in an inert vehicle containing alcohol (71% v/v), propylene glycol, acetone, and purified water.

As a topical repigmenting agent in vitiligo in conjunction with controlled doses of ultraviolet A (320-400 nm) or sunlight.

See all Oxsoralen Topical indications & dosage >>


Media Articles Related to Oxsoralen Topical (Methoxsalen Topical)

Vitiligo: A Common Cause of Loss of Skin Pigment
Source: MedicineNet Vitiligo Specialty [2014.12.01]
Title: Vitiligo: A Common Cause of Loss of Skin Pigment
Category: Doctor's Views
Created: 6/2/2005 12:00:00 AM
Last Editorial Review: 12/1/2014 12:00:00 AM

Source: MedicineNet Achalasia Specialty [2014.11.01]
Title: Vitiligo
Category: Diseases and Conditions
Created: 7/11/1999 12:00:00 AM
Last Editorial Review: 11/1/2014 12:00:00 AM

more news >>

Published Studies Related to Oxsoralen Topical (Methoxsalen Topical)

An intraindividual study of the characteristics of erythema induced by bath and oral methoxsalen photochemotherapy and narrowband ultraviolet B. [2003.07]
We compared the characteristics of psoralen and ultraviolet A (PUVA) erythema in skin photosensitized by bath or oral methoxsalen in 20 subjects. Erythema was assessed visually and with a reflectance instrument at 24 h intervals for 7 days.

The time course of topical PUVA erythema following 15- and 5-minute methoxsalen immersion. [2003.03]
CONCLUSIONS: Methoxsalen-UV-A erythema exhibited a broad plateau between 96 and 144 hours, with most subjects at peak erythema at 120 hours. Reduction of methoxsalen immersion time significantly lowered the erythemal intensity. Minimum phototoxic dose reading at 72 hours underestimates the phototoxic effect of topical methoxsalen PUVA, and a change in the MPD assessment time should be considered.

Microemulsions for topical delivery of 8-methoxsalen. [2000.10.03]
8-Methoxsalen (8-MOP) and related furocumarins have been extensively used for the treatment of hyperproliferative skin diseases in association with long-wavelength UVA light. In order to develop alternative formulations for the topical administration of 8-MOP, microemulsions were evaluated as delivery vehicles...

more studies >>

Clinical Trials Related to Oxsoralen Topical (Methoxsalen Topical)

A Safety and Efficacy Study of Uvadex and Extracorporeal Photopheresis (ECP) in Chronic Graft Versus Host Disease [Recruiting]
The purpose of this study is to evaluate the safety and effectiveness of extracorporeal photopheresis therapy when added to standard drug therapies administered to patients with moderate to severe chronic graft-versus-host disease.

Fumaric Acid Ester-PUVA Therapy Versus Acitretin -PUVA Therapy in Pustular Palmoplantar Psoriasis [Recruiting]
The purpose of this prospective, randomized, controlled, single-blinded investigation is to study the efficacy, tolerability and safety of oral photochemotherapy (PUVA) combined with acitretin versus oral PUVA combined with systemic fumaric acid esters (FAE) in patients with pustular palmoplantar psoriasis.

Patients will be randomized and allocated in concealed manner to one of the two treatment arms: acitretin-PUVA or FAE-PUVA.

RHIV A Pilot Study Refractory or Intolerant to Highly Active Antiretroviral Therapy (HAART) [Recruiting]
The objectives of this clinical trial are to:

- Assess the safety of using extracorporeal photoimmune therapy with the photosensitizing

agent Uvadex in the treatment of HIV-1 infection;

- Evaluate the effects of this therapy on HIV-1 viral load by polymerase chain reaction

(PCR) analysis;

- Evaluate the effects of this therapy on CD4+, CD8+ cells and CD4/CD8 ratio;

- Evaluate the effects of this therapy on the patient's immune system, by skin reactivity

to a standard anergy panel.

Safety and Efficacy Study of Photopheresis With UVADEX to Prevent Graft-Versus-Host Disease [Active, not recruiting]
The purpose of this study is to determine whether Extracorporeal Photopheresis with UVADEX (ECP) prior to bone marrow or peripheral blood stem cell transplantation is effective in the prevention of Graft-versus-Host Disease (GvHD).

Safety and Efficacy of Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Crohn's Disease [Active, not recruiting]
his study will explore the safety and activity of ECP treatment with UVADEX in inducing a clinical response (i. e., a CDAI decrease greater than or equal to 100 from baseline and/or a CDAI < 150) over a 12-week period in moderately active Crohn’s disease (CDAI greater than or equal to 220 to < 450) patients who are refractory or intolerant to immunosuppressants and/or anti-TNF agents. This study will also assess response to continued treatment during a 12-week Extension Period in patients who have a clinical response at Week 12 of the Treatment Period and elect to participate in the Extension Period.

more trials >>

Page last updated: 2014-12-01

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015